Epilepsy control with carbamazepine monotherapy from a genetic perspective

Table 4 MTHFR (C677T and A1298C) gene polymorphisms with its relative frequencies in poor seizures controlled and seizure controlled patients at 3^rd month of carbamazepine monotherapy

N = 71	Carbamazepine non-responsive patients (n = 46)	Carbamazepine responsive patients (n = 25)
Variables	Total	Total
Number (%)	46 (65)	25 (35)
Genotypes
677CC	14	16
677CT	21	4
677TT	11	5
1298AA	13	17
1298 AC	22	5
1298CC	11	3

MTHFR (C677T) Gene
Heterozygous (677CT) were more likely frequent in carbamazepine resistant patients compared to carbamazepine responsive patients in Pakhtun population of KP (χ² = 6.75, P = 0.009)*) comparing total patients of carbamazepine resistant VS total patients who are responsive to carbamazepine therapy.
However, homozygous mutant (677TT) genotypes were less likely associated with carbamazepine therapy resistant patients as compared to carbamazepine responsive patients (χ2 = 1.5, P = 0.026)
MTHFR (A1298C) Gene
Heterozygous (1298 AC) genotypes were more likely frequent in carbamazepine resistant patients compared to carbamazepine responsive patients (χ² = 7.2, P = 0.007**) comparing total patients of carbamazepine resistant VS total patients who are responsive to carbamazepine therapy.
However, homozygous mutant (1298CC) genotypes were less likely associated with carbamazepine therapy resistant patients as compared to carbamazepine responsive patients (χ² = 3.5, P = 0.05).

ISSN: 2050-6511